Stryker Corporation combines a near-perfect financial quality score with 13% analyst upside potential from $308, but a confirmed technical downtrend marked by a death cross and price below the 200-day moving average represents a meaningful timing risk that investors must weigh before establishing or adding to a position.
Thesis pillars
- Top Tier Financial Quality↓Deteriorating
- Analyst Upside Consensus Target↓Deteriorating
- Confirmed Technical Downtrend↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 11, 2026· older than 90 days
Stryker Corporation (SYK) Stock Analysis
Recovery setup
Healthcare · Medical Devices
Sell if holding. At $339.65, A.R:R is negative (-0.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: MedSurg and Neurotechnology (62.0%); Concentration risk — Supplier: sole-source suppliers.
Stryker manufactures and sells medical devices and technologies across two segments: MedSurg and Neurotechnology ($15.6 billion, 62% of net sales) and Orthopaedics ($9.5 billion, 38%), with products sold in approximately 61 countries. The company reported $25.1 billion in total... Read more
Sell if holding. At $339.65, A.R:R is negative (-0.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: MedSurg and Neurotechnology (62.0%); Concentration risk — Supplier: sole-source suppliers. Chart setup: Death cross but MACD improving, RSI 71. Score 5.2/10, moderate confidence.
Passes 6/9 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 84d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About Stryker Corporation
About Stryker Corporation
Stryker generated $25.1 billion in net sales in 2025, split between the MedSurg and Neurotechnology segment at $15.6 billion (62%) and the Orthopaedics segment at $9.5 billion (38%), with products sold in approximately 61 countries. The Mako SmartRobotics platform is deployed in more than 45 countries, and more than two million cumulative robotic procedures have been performed globally across total knee, total hip, and partial knee applications. The company employed approximately 56,000 people globally at December 31, 2025.
Stryker sells medical devices directly to hospitals and healthcare facilities, with indirect distribution channels used in markets where direct access is limited. Within MedSurg and Neurotechnology, Medical contributed $4.2 billion (27% of the segment), Endoscopy $3.8 billion (24%), Instruments $3.2 billion (20%), Neuro Cranial $2.5 billion (16%), and Vascular $2.0 billion (13%) in 2025. Within Orthopaedics, Trauma and Extremities led at $3.9 billion (42%), followed by Knees at $2.7 billion (28%) and Hips at $1.9 billion (20%). Competitors in Instruments include Zimmer Biomet, Medtronic, Johnson & Johnson MedTech, and ConMed Linvatec; in joint replacement, Stryker competes with Zimmer, Johnson & Johnson MedTech, and Smith & Nephew. Certain raw materials, components, and finished devices are procured from sole-source suppliers due to quality, intellectual property, and regulatory validation requirements, which may expose the company to product shortages if those suppliers face disruptions. Stryker acquired Inari Medical in 2025, integrating it into the Vascular business unit.
Show full overview
Stryker's products are subject to the European Union Medical Device Regulation, which imposes stricter clinical, quality, and post-market surveillance requirements with staggered compliance deadlines ranging from May 2026 through December 2028 depending on device type. China has implemented a volume-based procurement process for medical devices that has increased pricing pressure in that market. Tariffs enacted by the United States government and potential retaliatory measures by trading partners may further constrain supply chain availability. In May 2026, Stryker disclosed via Form 8-K that Vice President and Chief Accounting Officer William E. Berry Jr. will retire effective September 1, 2026, with Emily Baculik, current Corporate Controller, named as successor Chief Accounting Officer.
See also: Healthcare · Medical Devices
From Stryker Corporation's most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated Nov 4, 2026Recent Developments — Stryker Corporation
Latest news
- NEWS Stryker Files Prospectus For Offering Mixed Shelf; Terms Undisclosed — benzinga Nov 4, 2026 neutral
- NEWS SYK Q3 Earnings: Can Recovery Momentum Offset Operational Headwinds? - TradingView — TradingView Oct 28, 2026 negative
- NEWS Fund Update: 951,061 STRYKER (SYK) shares added to FLOSSBACH VON STORCH SE portfolio - Quiver Quantitative — Quiver Quantitative Oct 28, 2026 neutral
- NEWS Stryker (SYK) to report earnings tomorrow: here is what to expect - Yahoo Finance — Yahoo Finance Oct 28, 2026 neutral
- NEWS Stryker (SYK) to report earnings tomorrow: here is what to expect - StockStory — StockStory Oct 28, 2026 neutral
Latest item Nov 4, 2026 · Generated 2026-11-05T11:59:11Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductMedSurg and Neurotechnology62%10-K Item 1: 'MedSurg and Neurotechnology | $15,647 | 62%'
- HIGHSuppliersole-source suppliers10-K Item 1A: 'several raw materials, components, finished devices and services are procured from a sole source due to...quality considerations, unique intellectual property considerations or constraints associated with regulatory requirements'
Material Events(8-K, last 90d)
- 2026-05-20Item 5.02MEDIUMVP and Chief Accounting Officer William E. Berry Jr. to retire effective September 1, 2026. Emily Baculik, current VP/Corporate Controller, named as successor Chief Accounting Officer effective the same date.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $339.65, A.R:R is negative (-0.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: MedSurg and Neurotechnology (62.0%); Concentration risk — Supplier: sole-source suppliers. Chart setup: Death cross but MACD improving, RSI 71. Prior stop was $315.87. Score 5.2/10, moderate confidence.
Analyst target $306.44 reached (−9.8% from $339.65); no take-profit level is published. Prior stop was $315.87. Stop-loss: $315.87.
Concentration risk — Product: MedSurg and Neurotechnology (62.0%); Concentration risk — Supplier: sole-source suppliers; Analyst target reached - limited upside remaining.
Stryker Corporation trades at a P/E of 36.2 (forward 20.8). TrendMatrix value score: 4.6/10. Verdict: Sell.
35 analysts rate SYK, with a consensus score of 4.1/5. 27 analysts publish price targets averaging $340.
What does Stryker Corporation do?Stryker manufactures and sells medical devices and technologies across two segments: MedSurg and Neurotechnology ($15.6...
Stryker manufactures and sells medical devices and technologies across two segments: MedSurg and Neurotechnology ($15.6 billion, 62% of net sales) and Orthopaedics ($9.5 billion, 38%), with products sold in approximately 61 countries. The company reported $25.1 billion in total net sales for 2025, employing approximately 56,000 people globally. Mako SmartRobotics for joint replacement is available in more than 45 countries, with over two million robotic procedures performed to date.